Literature DB >> 26833121

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.

Jesus Delgado-Calle1, Judith Anderson2, Meloney D Cregor3, Masahiro Hiasa2, John M Chirgwin4, Nadia Carlesso5, Toshiyuki Yoneda2, Khalid S Mohammad6, Lilian I Plotkin1, G David Roodman7, Teresita Bellido8.   

Abstract

In multiple myeloma, an overabundance of monoclonal plasma cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bone resorption and suppressed bone formation. Matrix-embedded osteocytes comprise more than 95% of bone cells and are major regulators of osteoclast and osteoblast activity, but their contribution to multiple myeloma growth and bone disease is unknown. Here, we report that osteocytes in a mouse model of human MM physically interact with multiple myeloma cells in vivo, undergo caspase-3-dependent apoptosis, and express higher RANKL (TNFSF11) and sclerostin levels than osteocytes in control mice. Mechanistic studies revealed that osteocyte apoptosis was initiated by multiple myeloma cell-mediated activation of Notch signaling and was further amplified by multiple myeloma cell-secreted TNF. The induction of apoptosis increased osteocytic Rankl expression, the osteocytic Rankl/Opg (TNFRSF11B) ratio, and the ability of osteocytes to attract osteoclast precursors to induce local bone resorption. Furthermore, osteocytes in contact with multiple myeloma cells expressed high levels of Sost/sclerostin, leading to a reduction in Wnt signaling and subsequent inhibition of osteoblast differentiation. Importantly, direct contact between osteocytes and multiple myeloma cells reciprocally activated Notch signaling and increased Notch receptor expression, particularly Notch3 and 4, stimulating multiple myeloma cell growth. These studies reveal a previously unknown role for bidirectional Notch signaling that enhances MM growth and bone disease, suggesting that targeting osteocyte-multiple myeloma cell interactions through specific Notch receptor blockade may represent a promising treatment strategy in multiple myeloma. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26833121      PMCID: PMC4775415          DOI: 10.1158/0008-5472.CAN-15-1703

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Notch signaling induces apoptosis in primary human CD34+ hematopoietic progenitor cells.

Authors:  Nicholas Chadwick; Maria Cristina Nostro; Martin Baron; Rachel Mottram; Gerard Brady; Anne-Marie Buckle
Journal:  Stem Cells       Date:  2006-09-14       Impact factor: 6.277

2.  Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT.

Authors:  Maria Almeida; Li Han; Teresita Bellido; Stavros C Manolagas; Stavroula Kousteni
Journal:  J Biol Chem       Date:  2005-10-25       Impact factor: 5.157

3.  Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.

Authors:  Nicola Giuliani; Simona Colla; Francesca Morandi; Mirca Lazzaretti; Roberto Sala; Sabrina Bonomini; Maria Grano; Silvia Colucci; Mirija Svaldi; Vittorio Rizzoli
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

Review 4.  Chemokines in multiple myeloma.

Authors:  Rohit Aggarwal; Irene M Ghobrial; G David Roodman
Journal:  Exp Hematol       Date:  2006-10       Impact factor: 3.084

5.  Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

Authors:  Ming Li; Feng Chen; Nicholas Clifton; Daniel M Sullivan; William S Dalton; Dmitry I Gabrilovich; Yulia Nefedova
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

Review 6.  Targeting the bone microenvironment in multiple myeloma.

Authors:  G David Roodman
Journal:  J Bone Miner Metab       Date:  2010-02-04       Impact factor: 2.626

7.  Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.

Authors:  Sathish Kumar Mungamuri; Xiaohe Yang; Ann D Thor; Kumaravel Somasundaram
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 8.  Pathogenesis of myeloma bone disease.

Authors:  G D Roodman
Journal:  Leukemia       Date:  2008-11-27       Impact factor: 11.528

9.  Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.

Authors:  Thomas L Andersen; Kent Søe; Teis E Sondergaard; Torben Plesner; Jean-Marie Delaisse
Journal:  Br J Haematol       Date:  2009-11-16       Impact factor: 6.998

Review 10.  Notch signalling: a simple pathway becomes complex.

Authors:  Sarah J Bray
Journal:  Nat Rev Mol Cell Biol       Date:  2006-09       Impact factor: 94.444

View more
  76 in total

Review 1.  Notch and the regulation of osteoclast differentiation and function.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  Bone       Date:  2020-06-08       Impact factor: 4.398

2.  MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.

Authors:  Jesus Delgado-Calle; Benjamin Hancock; Elive F Likine; Amy Y Sato; Kevin McAndrews; Carolina Sanudo; Angela Bruzzaniti; Jose A Riancho; James R Tonra; Teresita Bellido
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 3.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

Review 4.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

5.  Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice.

Authors:  Hannah M Davis; Alyson L Essex; Sinai Valdez; Padmini J Deosthale; Mohammad W Aref; Matthew R Allen; Andrea Bonetto; Lilian I Plotkin
Journal:  Bone       Date:  2019-04-24       Impact factor: 4.398

6.  Ex vivo construction of human primary 3D-networked osteocytes.

Authors:  Qiaoling Sun; Saba Choudhary; Ciaran Mannion; Yair Kissin; Jenny Zilberberg; Woo Y Lee
Journal:  Bone       Date:  2017-09-21       Impact factor: 4.398

Review 7.  Sclerostin expression and functions beyond the osteocyte.

Authors:  Megan M Weivoda; Stephanie J Youssef; Merry Jo Oursler
Journal:  Bone       Date:  2016-11-23       Impact factor: 4.398

8.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

Authors:  Michelle M McDonald; Michaela R Reagan; Scott E Youlten; Sindhu T Mohanty; Anja Seckinger; Rachael L Terry; Jessica A Pettitt; Marija K Simic; Tegan L Cheng; Alyson Morse; Lawrence M T Le; David Abi-Hanna; Ina Kramer; Carolyne Falank; Heather Fairfield; Irene M Ghobrial; Paul A Baldock; David G Little; Michaela Kneissel; Karin Vanderkerken; J H Duncan Bassett; Graham R Williams; Babatunde O Oyajobi; Dirk Hose; Tri G Phan; Peter I Croucher
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

Review 9.  MicroRNA Exert Macro Effects on Cancer Bone Metastasis.

Authors:  Scott R Baier; Yihong Wan
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 10.  Adipose, Bone, and Myeloma: Contributions from the Microenvironment.

Authors:  Michelle M McDonald; Heather Fairfield; Carolyne Falank; Michaela R Reagan
Journal:  Calcif Tissue Int       Date:  2016-06-24       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.